Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) kicked off on Tuesday, down -5.17% from the previous trading day, before settling in for the closing price of $19.92. Over the past 52 weeks, ARWR has traded in a range of $17.05-$36.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -2.87%. While this was happening, its average annual earnings per share was recorded 48.37%. With a float of $116.41 million, this company’s outstanding shares have now reached $125.57 million.
Let’s determine the extent of company efficiency that accounts for 609 employees. In terms of profitability, gross margin is -272.28%, operating margin of -25037.88%, and the pretax margin is -25870.12%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc is 6.93%, while institutional ownership is 75.87%. The most recent insider transaction that took place on Jan 23 ’25, was worth 20,139. In this transaction Director of this company sold 959 shares at a rate of $21.00, taking the stock ownership to the 35,781 shares. Before that another transaction happened on Jan 23 ’25, when Company’s Director proposed sale 959 for $20.97, making the entire transaction worth $20,108.
Arrowhead Pharmaceuticals Inc (ARWR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 48.37% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Take a look at Arrowhead Pharmaceuticals Inc’s (ARWR) current performance indicators. Last quarter, stock had a quick ratio of 6.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 945.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.15, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -3.60 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Looking closely at Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR), its last 5-days average volume was 1.44 million, which is a drop from its year-to-date volume of 2.37 million. As of the previous 9 days, the stock’s Stochastic %D was 37.15%. Additionally, its Average True Range was 1.14.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 17.88%, which indicates a significant decrease from 18.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.45% in the past 14 days, which was lower than the 66.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.77, while its 200-day Moving Average is $22.57. However, in the short run, Arrowhead Pharmaceuticals Inc’s stock first resistance to watch stands at $19.72. Second resistance stands at $20.54. The third major resistance level sits at $21.29. If the price goes on to break the first support level at $18.15, it is likely to go to the next support level at $17.40. Should the price break the second support level, the third support level stands at $16.58.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
The company with the Market Capitalisation of 2.36 billion has total of 125,073K Shares Outstanding. Its annual sales at the moment are 3,550 K in contrast with the sum of -599,490 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -170,540 K.
